Status:
COMPLETED
The Effects of Cilnidipine on Metabolic Syndrome Improvement
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Conditions:
Hypertension
Metabolic Syndrome X
Eligibility:
All Genders
30-65 years
Phase:
PHASE4
Brief Summary
Abnormalities of glucose, insulin and lipoprotein metabolism are common in patients with hypertension, and these metabolic abnormalities are reported to be related to insulin resistance. Therefore, wh...
Detailed Description
* Multi-center, randomized, prospective, double blind, active control, parallel study * Superiority study (Treatment group - Cilnidipine/Control group - Nifedipine) * Measure the effects of Cinalong(T...
Eligibility Criteria
Inclusion
- Men or women, 30-65 years of age having essential hypertension with metabolic syndrome
- At Screening and Visit 1, blood pressure should be: sitting systolic blood pressure (SiSBP) \>=140 mmHg or sitting diastolic blood pressure (SiDBP)\>= 90 mmHg and two or more of the following criteria should apply.
- Abdominal obesity: waist circumference \>= 90 cm in men and \>= 80 cm in women
- Hypertriglyceridemia:. \>=150 mg/dl (1.695 mmol/l)
- Low HDL cholesterol: \< 40 mg/dl (1.036 mmol/l) in men and \< 50 mg/dl (1.295 mmol/l) in women
- High fasting glucose: \>= 110 mg/dl (6.1 mmol/l)
Exclusion
- Secondary hypertension
- Malignant hypertension
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT00325936
Start Date
July 1 2005
End Date
June 1 2007
Last Update
August 27 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cheil general hospital
Seoul, South Korea, 100-380